Breast Cancer — BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors
Citation(s)
Multicenter Parallel Phase II Trial of BI 2536 Administered as One Hour IV Infusion Every 3 Weeks in Defined Cohorts of Patients With Various Solid Tumors. A New Drug Screening Program of the EORTC Network of Core Institutions (NOCI)